Zoetis (NYSE:ZTS) Reaches New 52-Week Low – Should You Sell?

Zoetis Inc. (NYSE:ZTS) reached a new 52-week low during trading on Monday . The stock traded as low as $70.54 and last traded at $70.6070, with a volume of 434683 shares changing hands. The stock had previously closed at $71.40.

Analysts Set New Price Targets

ZTS has been the subject of a number of analyst reports. Stifel Nicolaus cut their price target on Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a research note on Thursday, August 20th. TD Cowen lowered their price target on Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 25th. Citigroup cut their price objective on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Argus reiterated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Finally, UBS Group cut their price target on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $101.08.

Zoetis Stock Performance

The company’s fifty day simple moving average is $75.31 and its 200 day simple moving average is $89.74. The stock has a market capitalization of $29.39 billion, a P/E ratio of 11.70, a P/E/G ratio of 1.67 and a beta of 0.73. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm’s quarterly revenue was down .2% on a year-over-year basis. During the same quarter last year, the company earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zoetis

Hedge funds have recently bought and sold shares of the stock. Physician Wealth Advisors Inc. raised its stake in shares of Zoetis by 17.4% during the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock valued at $73,000 after acquiring an additional 91 shares during the last quarter. Smithfield Trust Co grew its stake in shares of Zoetis by 4.2% in the fourth quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock worth $290,000 after purchasing an additional 92 shares during the last quarter. Brown Lisle Cummings Inc. grew its stake in shares of Zoetis by 6.3% in the first quarter. Brown Lisle Cummings Inc. now owns 1,621 shares of the company’s stock worth $192,000 after purchasing an additional 96 shares during the last quarter. Lipe & Dalton increased its holdings in Zoetis by 2.2% during the 1st quarter. Lipe & Dalton now owns 4,698 shares of the company’s stock valued at $555,000 after purchasing an additional 102 shares during the period. Finally, Riverwater Partners LLC increased its holdings in Zoetis by 3.6% during the 4th quarter. Riverwater Partners LLC now owns 2,949 shares of the company’s stock valued at $371,000 after purchasing an additional 103 shares during the period. 92.80% of the stock is currently owned by institutional investors.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company’s product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.